Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved PROTELOS opvejer risiciene til behandling af knogleskørhed hos kvinder efter overgangsalderen til mindskelse af risikoen for rygsøjlebrud og hoftebrud.
The Committee for Medicinal Products for Human Use (CHMP) decided that PROTELOS’ s benefits are greater than its risks for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fractures.